secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001437749-24-029012
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar reports positive early human data for MNPR-101-Zr tumor targeting
-------------------------------------------------------------------------

- MNPR-101-Zr PET image at 168h post-dose in first cancer patient shows high preferential uptake in metastatic tumors.
- Uptake aligns with FDG-PET locations; imaging performed on high-sensitivity Siemens Biograph Vision Quadra scanner.
- Company aims to launch MNPR-101-Lu Phase 1 therapeutic trial in Q4 2024.
- Additional data to be presented at EANM 2024 Congress (Oct 19-23) as 'Top-Rated Oral Presentation'.
- MNPR-101 targets uPAR, expressed in majority of triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924029012/0001437749-24-029012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924029012/mnpr20240911_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-029012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer